Month: September 2024

“Lumbosacral Radicular Pain Market”

According to the latest report, “Lumbosacral Radicular Pain Market Insights, Epidemiology, and Market Forecast 2032” from DelveInsight, the market for lumbosacral radicular pain is expected to experience significant growth from 2019 to 2032. 

The market dynamics are projected to evolve due to increasing interest from pharmaceutical companies in developing new treatments, advancements in diagnostic methods, and the anticipated launch of emerging therapies. The report provides detailed insights into current treatment practices, the pipeline of upcoming drugs, market shares of individual therapies, and forecasts the market size trajectory from 2019 to 2032 across the 7MM (the United States, EU-4 countries—Italy, Spain, France, and Germany—the United Kingdom, and Japan).

Discover the Anticipated Evolution and Growth of the Market @ Lumbosacral Radicular Pain Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

• Lumbosacral Radicular Pain Clinical Trial Progression: The market is poised for substantial growth, fueled by the anticipated launch of emerging therapies between 2023 and 2032. Leading companies such as Scilex Pharmaceuticals, Inc., Semnur Pharmaceuticals, Inc., Teva Branded Pharmaceutical Products R&D, Inc., and Cephalon, among others, are actively working on innovative drugs for potential market introduction.

• Lumbosacral Radicular Pain Innovative Therapies: Ongoing research and development efforts are paving the way for innovative therapies aimed at alleviating the signs and symptoms of lumbosacral radicular pain. Therapies such as SP-102 and Placulumab, among others, are playing a significant role in advancing the lumbosacral radicular pain market.

Lumbosacral Radicular Pain Market Dynamics

In recent decades, research into lumbosacral radicular pain (LRP) has significantly increased. Low back pain (LBP) poses both a substantial medical challenge and a considerable economic burden worldwide. Despite growing efforts to manage LBP, its prevalence and associated disability continue to rise, making effective management of LRP a major concern for healthcare professionals.

When considering transforaminal Epidural Steroid Injections (ESIs), the use of particulate corticosteroids raises the risk of complications. Nonparticulate corticosteroids, often recommended as initial treatments, may provide only temporary relief and are sometimes formulated with neurotoxic preservatives. Enhancing the safety profile of ESIs could involve developing safer, sterile formulations that reduce complications while maintaining efficacy.

Several companies, including Scilex Pharmaceuticals, Inc., Semnur Pharmaceuticals, Inc., Teva Branded Pharmaceutical Products R&D, Inc., and Cephalon, are actively working on new therapies to address the gaps in current treatments. The expanding range of developmental strategies, coupled with anticipated submissions to the US FDA, suggests that specialized therapies for LRP could emerge within the forecast period of 2021–2032. Additionally, a deeper understanding of the disease’s pathogenesis is expected to drive the development of innovative treatments for lumbosacral radicular pain.

Request for a sample report @ https://www.delveinsight.com/sample-request/lumbosacral-radicular-pain-market

Leading Lumbosacral Radicular Pain Companies and Emerging Drugs: Leading companies such as Scilex Pharmaceuticals, Inc., Semnur Pharmaceuticals, Inc., Teva Branded Pharmaceutical Products R&D, Inc., and Cephalon, among others, are actively working on developing innovative drugs for potential introduction into the lumbosacral radicular pain market.

Lumbosacral Radicular Pain Therapeutic Landscape: Notable therapies for treating lumbosacral radicular pain include SP-102, Placulumab, and others.

Lumbosacral Radicular Pain Overview:

Lumbosacral radicular pain is characterized by radiating discomfort that affects one or more lumbar or sacral dermatomes. This pain may be accompanied by additional radicular symptoms or reduced function. It can start acutely, often due to an injury, but has the potential to become chronic if not managed effectively. Early and appropriate management of the pain can help minimize both the duration and severity of symptoms. 

The pain is generally categorized into three types: acute, chronic, and neuropathic. Each patient’s experience of lumbar pain can vary, but common complaints associated with lumbar radiculopathy include pain, tingling, numbness, weakness, and loss of reflexes. These symptoms typically occur in the lower back, buttocks, legs, and feet. Although the pain may radiate to either leg, it usually affects only one leg.

Key Facts Lumbosacral Radicular Pain Market Report:

• Key players such as Scilex Pharmaceuticals, Inc., Semnur Pharmaceuticals, Inc., Teva Branded Pharmaceutical Products R&D, Inc., and Cephalon, among others, are actively researching potential candidates for lumbosacral radicular pain.

• The lumbosacral radicular pain pipeline features major therapies including SP-102, Placulumab, and others. Growing awareness is shaping the current therapeutic landscape across the 7MM. The market for lumbosacral radicular pain, valued at USD XX million in 2020, is projected to grow significantly by 2032.

• According to BMUS: The Burden of Musculoskeletal Diseases in the United States, nearly 29% of the US population aged 18 and older self-reported experiencing lumbosacral radicular pain annually.

Lumbosacral Radicular Pain Epidemiology Segmentation:

• According to Khorami et al. (2021), the annual prevalence of lumbosacral radicular pain—defined as low back pain with leg pain extending below the knee—ranges from 9.9% to 25% in the general population. The point prevalence varies between 4.6% and 13.4%, while the lifetime prevalence ranges from 1.2% to 43%. These figures suggest that lumbosacral radicular pain is likely one of the most common forms of neuropathic pain.

• The report on lumbosacral radicular pain epidemiology includes both historical and projected data. It covers the total prevalence of lumbosacral radicular pain, the number of diagnosed and treatable cases, and prevalence segmented by age and gender. The analysis encompasses the 7MM (United States, EU4 countries—Germany, France, Italy, Spain—and the United Kingdom) and Japan, spanning from 2019 to 2032.

The Lumbosacral Radicular Pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Lumbosacral Radicular Pain

• Prevalent Cases of Lumbosacral Radicular Pain by severity

• Gender-specific Prevalence of Lumbosacral Radicular Pain

• Type-specific Prevalence of Lumbosacral Radicular Pain

• Age-specific Prevalence of Lumbosacral Radicular Pain

• Diagnosed Cases of Lumbosacral Radicular Pain

DelveInsight’s comprehensive report provides a thorough exploration of the Lumbosacral Radicular Pain market, covering key Lumbosacral Radicular Pain players, emerging Lumbosacral Radicular Pain therapies, treatment dynamics, and market challenges.

Lumbosacral Radicular Pain Emerging Drugs

• SP-102: Semnur Pharmaceuticals

For in-depth insights, access the full report @ Lumbosacral Radicular Pain Market Outlook 2032

DelveInsight’s report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Lumbosacral Radicular Pain market landscapes

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lumbosacral Radicular Pain Market Growth Anticipated by 2032 | Companies includes Scilex Pharmaceuticals, Inc., Semnur Pharmaceuticals, Teva BrandedPharmaceutical Products R&D, Cephalon

“Obsessive Compulsive Disorder Market”

According to the latest DelveInsight report, titled “Obsessive Compulsive Disorder Market Insights, Epidemiology and Market Forecast 2034,” the market for Obsessive Compulsive Disorder (OCD) is projected to experience substantial growth between 2020 and 2034. Advances in understanding the disease mechanisms have led to the development of new diagnostic and therapeutic approaches, which are expected to drive drug innovation and market expansion. This positive trend is primarily fueled by an increase in OCD cases and the introduction of new therapies over the forecast period.

The report provides a comprehensive overview of current treatment practices for OCD, details upcoming drugs in the pipeline, analyzes the market share of various therapies, and forecasts the market size from 2020 to 2034 across the seven major markets (7MM), which include the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan.

Driving Forces Behind the Obsessive Compulsive Disorder Market Growth

The rising prevalence of Obsessive Compulsive Disorder is driving research and the development of new therapies, creating a favorable environment for the potential success of innovative products.

Discover the Anticipated Evolution and Growth of the Market @ Obsessive Compulsive Disorder Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

• Obsessive Compulsive Disorder Clinical Trial Progression: The market is poised for substantial growth, fueled by the introduction of emerging therapies anticipated between 2023 and 2034. Leading companies, such as Biohaven Pharmaceuticals and others, are actively developing innovative drugs for potential entry into the market.

• Obsessive Compulsive Disorder Innovative Therapies: Ongoing research and development efforts are paving the way for the introduction of new therapies aimed at addressing the symptoms of Obsessive Compulsive Disorder. Treatments like Troriluzole, among others, are significantly contributing to the growth of the OCD market.

Obsessive Compulsive Disorder Market Dynamics

“The outcome regarding pipeline therapies’ success in addressing relapse, treatment resistance, and side effects will significantly influence their impact on overall revenue generation.”

Currently, there is a notable scarcity of clinical developments targeting obsessive-compulsive disorder (OCD). Secondary searches across databases such as NIH ClinicalTrials.gov and EudraCT reveal that only a handful of companies are actively working on drug candidates in clinical stages. One such company is Biohaven Pharmaceuticals, which is investigating its drug asset in a clinical study. The anticipated launch of this emerging therapy is expected to positively influence the OCD market, with detailed descriptions available in the report’s section on emerging drugs.

Troriluzole, a third-generation prodrug and new chemical entity, modulates glutamate, the primary excitatory neurotransmitter in the brain. Its main mechanism involves reducing synaptic glutamate levels by enhancing its uptake through excitatory amino acid transporters on glial cells, which are essential for clearing glutamate from the synapse.

Compared to its active metabolite, riluzole, troriluzole offers improved bioavailability, pharmacokinetics, tolerability, and dosing. Based on its action mechanism, preclinical data, and clinical studies, troriluzole shows promise for treating neurological and neuropsychiatric disorders. Its potential for OCD is supported by clinical data on riluzole, including open-label and placebo-controlled trials, as well as preclinical, genetic, and neuroimaging studies that suggest glutamatergic hyperactivity plays a role in OCD.

Currently, troriluzole is being evaluated in three ongoing Phase III trials and one Phase II/III trial targeting adults with a primary diagnosis of OCD, as defined by DSM-5 criteria.

Obsessive Compulsive Disorder Market

OCD can be managed through pharmacotherapy, specialized psychotherapy, anatomically targeted treatments, or a combination of these approaches. The primary treatments include cognitive-behavioral therapy (CBT) and pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs). This article focuses on evidence-based pharmacotherapies for OCD and considers alternatives for patients who are resistant to standard treatments. Other treatment modalities are discussed in separate articles in this issue.

Despite optimal treatment, many patients still experience significant symptoms, with remission of moderate to severe OCD being rare. Long-term management is often required, highlighting the urgent need for more effective interventions.

New treatment options with novel mechanisms, such as SSRIs, serotonin uptake inhibitors, and glutamate release inhibitors, are being developed by key players including Jazz Pharmaceuticals, Eli Lilly and Company, Biohaven, Spec GX (Mallinckrodt), and Apotex.

In conclusion, while current treatments may be insufficient, emerging therapies with innovative mechanisms are expected to address critical unmet needs and improve outcomes for OCD patients. With the anticipated availability of new treatments and increased healthcare investment across the 7MM, the OCD treatment landscape is projected to grow significantly during the forecast period (2024–2034).

Obsessive Compulsive Disorder Treatment Market

Obsessive-compulsive disorder (OCD) profoundly affects quality of life, leading to social isolation and imposing a significant economic burden on society.

The treatment of OCD involves a multi-faceted approach. It begins with establishing a therapeutic relationship with the patient and providing psychoeducation, followed by psychological and/or pharmacological interventions. For those with treatment-resistant OCD, options like neuromodulation and neurosurgery may be considered, though these alternative treatments require further validation. While general management principles exist, tailoring treatments to individual needs is crucial. For example, some comorbid conditions like depression may respond to standard OCD pharmacotherapies, while others, such as bipolar disorder, might need additional treatments. Although similar pharmacotherapies and psychotherapies are used across various age groups, adjustments are necessary when treating children and adolescents.

Cognitive-behavioral therapy (CBT) is the most evidence-based psychotherapy for OCD. Meta-analyses of randomized controlled trials consistently show significant improvement in OCD symptoms for both adults and children undergoing CBT. CBT involves cognitive reappraisal and behavioral intervention, with Exposure and Response Prevention (ERP) being the specific technique for treating OCD. The International OCD Foundation suggests that if outpatient ERP is ineffective, more intensive care involving multiple sessions per week might be required, ranging from traditional outpatient to intensive outpatient treatments.

The most effective treatments for OCD are CBT and/or medication, specifically ERP and/or serotonin reuptake inhibitors (SRIs). ERP is typically administered by a licensed mental health professional in an outpatient setting, while medications are prescribed by licensed medical professionals and ideally coordinated with therapy.

OCD can be managed through pharmacotherapy, specialized psychotherapy, anatomically targeted treatments, or a combination of these approaches. First-line treatments include cognitive-behavioral therapy and pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs). However, a substantial number of patients may not respond to these initial treatments. Even with optimized CBT and enhanced pharmacologic treatment, around 10% of patients remain treatment-resistant.

Treatment-resistant OCD is a major source of suffering and disability among individuals with mental disorders. Second-line treatments include augmentation with antipsychotics, electroconvulsive therapy, transcranial magnetic stimulation, and deep brain stimulation (DBS). Despite the availability of these treatments, the greatest unmet need for OCD patients and their families remains access to appropriate pharmacotherapy and/or cognitive-behavioral therapy. Challenges related to treatment affordability, adequate medication dosing, treatment response information, and relapse prevention further complicate the issue.

Leading Obsessive Compulsive Disorder Companies and Emerging Drugs: Pioneering companies such as Biohaven Pharmaceuticals, among others, are actively developing novel drugs for potential entry into the Obsessive Compulsive Disorder market.

Obsessive Compulsive Disorder Therapeutic Landscape: Key therapies identified for Obsessive Compulsive Disorder treatment include Troriluzole, and more.

Obsessive Compulsive Disorder Overview:

Obsessive-Compulsive Disorder (OCD) is a mental health condition marked by persistent, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) that significantly disrupt daily life. 

Symptoms of OCD:

– Obsessions: Persistent, distressing thoughts or urges, such as fears of contamination, harming others, or needing extreme order.

– Compulsions: Repetitive actions or mental rituals performed to alleviate the distress from obsessions, like excessive handwashing or checking.

– Time-consuming: Both obsessions and compulsions can take up substantial time and disrupt daily activities, work, and relationships.

– Interference with life: OCD impairs functioning and impacts various life aspects, including relationships and social interactions.

– Insight: Many individuals recognize their obsessions and compulsions as irrational but struggle to control them.

Causes of OCD:

OCD’s exact cause is not fully understood but is believed to involve a mix of genetic, neurological, behavioral, cognitive, and environmental factors, with serotonin imbalances potentially playing a role.

Treatment for OCD:

– Therapy: Cognitive-behavioral therapy (CBT), particularly Exposure and Response Prevention (ERP), is the most effective treatment, helping individuals face their obsessions and refrain from compulsions.

– Medications: Selective serotonin reuptake inhibitors (SSRIs) are commonly used to regulate serotonin levels and alleviate symptoms.

– Self-help strategies: Techniques such as mindfulness, stress reduction, and support groups can complement formal treatment.

While OCD is a chronic condition, effective management through early intervention, therapy, and medication can help individuals lead fulfilling lives. Consulting a mental health professional is essential for accurate diagnosis and treatment.

Key Facts Obsessive Compulsive Disorder Market Report:

• In 2023, the market size for Obsessive-Compulsive Disorder (OCD) across the 7MM (United States, EU4, the United Kingdom, and Japan) was approximately USD 1 billion. The United States represents the largest segment, accounting for around USD 600 million, compared to the combined markets of the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

• Among the EU4 and the UK, Germany had the highest number of prevalent OCD cases, contributing about 33% of the total in 2023.

• Current treatment options include FDA-approved medications such as sertraline (ZOLOFT), fluoxetine (PROZAC), fluvoxamine (LUVOX), paroxetine (PAXIL), clomipramine (ANAFRANIL), and paroxetine mesylate (PEXEVA).

• According to DelveInsight’s analysis, BHV-4157 (troriluzole) is projected to become the leading drug in the OCD market during the forecast period from 2024 to 2034. The market dynamics are expected to evolve with advancements in understanding the disease and its pathophysiology. Biohaven Pharmaceuticals is actively investigating troriluzole as a treatment for OCD.

• In 2023, the United States held the largest share of the OCD market among the 7MM, representing approximately 55% of the total market. The OCD market size in the US was about USD 600 million.

• Selective serotonin reuptake inhibitors (SSRIs) generated around USD 290 million in revenue across the seven major markets in 2023, while antipsychotics followed with approximately USD 160 million. 

• The market size for OCD in the EU4 and the UK was approximately USD 380 million in 2023.

Obsessive Compulsive Disorder Epidemiology Segmentation:

• In 2023, the total number of diagnosed OCD cases in the United States was approximately 2.1 million. OCD in the US shows a higher prevalence in females, with about 78% of cases occurring in women and 22% in men. The overall prevalence of OCD is expected to rise for both genders in the coming years.

• Across the 7MM, the distribution of OCD cases in 2023 was approximately 320,000 mild cases, 760,000 moderate cases, and 1.1 million severe cases.

• In the EU4 and the UK, the gender distribution of OCD cases in 2023 was similar to the US, with around 22% of cases in males and 78% in females.

The Obsessive Compulsive Disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Obsessive Compulsive Disorder

• Prevalent Cases of Obsessive Compulsive Disorder by severity

• Gender-specific Prevalence of Obsessive Compulsive Disorder

• Type-specific Prevalence of Obsessive Compulsive Disorder

• Age-specific Prevalence of Obsessive Compulsive Disorder

• Diagnosed Cases of Obsessive Compulsive Disorder

DelveInsight’s comprehensive report provides a thorough exploration of the Obsessive Compulsive Disorder market, covering key Obsessive Compulsive Disorder players, emerging Obsessive Compulsive Disorder therapies, treatment dynamics, and market challenges.

For in-depth insights, access the full report @ Obsessive Compulsive Disorder Market Outlook 2034

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obsessive Compulsive Disorder Market Growth Anticipated by 2034 | Major Player: Biohaven Pharmaceuticals, expected to boost the market

“Meniscus Tear Market”

The market for meniscus tears is projected to experience significant growth from 2019 to 2032, according to the latest report titled “Meniscus Tear Market Insights, Epidemiology, and Market Forecast 2032” by DelveInsight.

The report provides a comprehensive overview of current treatment practices for meniscus tears, highlights upcoming drugs in the pipeline, and details the market shares of various therapies. It also outlines the anticipated trajectory of the meniscus tear market from 2019 to 2032 across the 7MM (the United States, EU-4 countries—Italy, Spain, France, and Germany—the United Kingdom, and Japan).

Driving Forces Behind the Meniscus Tear Market Growth

The primary driver behind the growth in the meniscus tear market size is the increasing number of incidents and prevalent cases.

Discover the Anticipated Evolution and Growth of the Market @ Meniscus Tear Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

• Meniscus Tear Clinical Trial Progression: The market is poised for substantial growth, fueled by the anticipated launch of emerging therapies between 2023 and 2032. Leading companies such as Smith & Nephew, Arcuro Medical, Zimmer Biomet Holdings, and others are actively developing innovative treatments for potential introduction to the market.

• Meniscus Tear Innovative Therapies: Ongoing research and development efforts are advancing the introduction of innovative devices aimed at addressing the signs and symptoms of meniscus tears. Medical devices such as the NOVOSTITCH PRO Meniscal Repair System, JuggarStitch, and the SuperBall Meniscus Repair System, among others, are driving growth in the meniscus tear market.

Meniscus Tear Market Dynamics

Smith & Nephew developed the FAST-FIXm, a meniscal repair method renowned for its durability, consistency, and efficiency. Biomechanical studies have shown that the vertical mattress suture performed with the FAST-FIX 360 Meniscal Repair System achieves biomechanical characteristics comparable to those of similar sutures executed using open and inside-out techniques.

In September 2020, Smith & Nephew launched the NOVOSTITCH PRO Meniscal Repair System in Europe after successfully obtaining CE mark certification. This system expands repair options for approximately 600,000 European patients annually who previously had only the option of meniscal removal. The NOVOSTITCH PRO Meniscal Repair System is also commercially available in the US, Europe, the Middle East, Africa, and selected other countries.

Zimmer Biomet Holdings received FDA clearance in September 2019 for the JuggerStitch meniscal repair device. This advanced technology, representing the next generation of meniscus repair tools, has achieved 510(k) clearance and is now available in the US market. The JuggerStitch features a unique design with two soft anchors connected by a knotless, self-locking suture loop, which aims to enhance tissue preservation and provide surgeons with better control over tissue compression compared to traditional sliding knot implants.

Additionally, in June 2020, Arcuro Medical received FDA approval for its SuperBall Meniscus Repair System.

Meniscus Tear Treatment Market

The therapeutic management of meniscus tears primarily involves the use of nonsteroidal anti-inflammatory drugs (NSAIDs), which help alleviate pain and reduce swelling around the knee. Unfortunately, there is no pharmacological cure for this condition. 

Current medical management for meniscus tears is often considered insufficient. However, the effectiveness of treatment can be greatly improved through the use of existing diagnostic, therapeutic, and preventative measures, as well as surgical interventions. Biologics, which are medicines derived from biological sources such as blood, bone marrow, and fat cells, represent an emerging technology. They hold potential as a complementary approach to nonsurgical treatments by aiding tissue repair and reducing knee inflammation.

According to DelveInsight, the meniscus tear market in the 7MM is expected to undergo significant changes during the study period from 2019 to 2032.

Leading Meniscus Tear Companies and Emerging Drugs: Leading companies like Smith & Nephew, Arcuro Medical, and Zimmer Biomet Holdings, among others, are actively working on developing innovative treatments for potential entry into the meniscus tear market.

Meniscus Tear Therapeutic Landscape: Medical devices used for treating meniscus tears include the NOVOSTITCH PRO Meniscal Repair System, JuggarStitch, SuperBall Meniscus Repair System, and others.

Meniscus Tear Overview:

A meniscus tear is an injury to one of the rubbery cartilage bands in the knee that act as shock absorbers. This type of tear can occur suddenly when the knee is twisted while the foot is fixed on the ground, or it can develop gradually as the meniscus loses its elasticity, leading to frayed edges. Meniscus tears are common knee injuries, particularly among athletes and recreational sports enthusiasts, as well as older individuals and those with arthritis. Symptoms typically include pain, swelling, stiffness, and difficulty extending the knee. Depending on the severity of the tear, surgery may or may not be required.

Diagnosis of a meniscus tear often begins with a physical examination, but may also involve imaging tests such as MRI, X-rays, and arthroscopy.

Management of a meniscus tear depends on factors such as the patient’s age, symptoms, and activity level. Treatment options are categorized into nonsurgical and surgical approaches. Nonsurgical treatments include rest, ice, compression, and elevation; medications to relieve pain; physical therapy; corticosteroid injections; and biologic injections. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen can help reduce inflammation and pain, while acetaminophen manages pain without addressing inflammation. Corticosteroids, though not healing the tear, can reduce swelling and discomfort when injected directly into the knee. Biologics, which are derived from biological sources such as blood, bone marrow, and fat cells, represent an emerging technology that may complement nonsurgical treatments by promoting tissue healing and reducing inflammation.

Key Facts Meniscus Tear Market Report:

• Key players such as Smith & Nephew, Arcuro Medical, Zimmer Biomet Holdings, and others are investigating its candidates for Meniscus Tear.

• Meniscus Tear pipeline includes the devices as NOVOSTITCH PRO Meniscal Repair System, JuggarStitch, SuperBall meniscus repair system, and others.

• Due to the positive results from key players in the meniscus repair systems market, such as Zimmer Biomet, Smith & Nephew, and Arcuro Medical, leading manufacturers are advancing their expertise with integrated technologies.

• Meniscal injuries are common, affecting approximately 61 individuals per 100,000, with a prevalence rate between 12% and 14%. The risk of meniscal tears increases significantly when accompanied by an anterior cruciate ligament (ACL) injury, with rates ranging from 22% to 86%. In the United States, out of an estimated 850,000 cases annually, about 10% to 20% of orthopedic surgeries involve meniscus repair. Acute meniscal tears are most frequently seen in men aged 21 to 30 and women aged 11 to 19, with a male-to-female ratio of 2.5:1 to 4:1. Conversely, degenerative meniscal tears are more common in men aged 40 to 60 years.

• The meniscus tear market is projected to experience steady growth throughout the forecast period (2023–2032), driven by the rising incidence of sports injuries, growing awareness of advanced medical technologies, and an increase in osteoarthritis cases, all of which are expected to boost revenue.

• DelveInsight analysts have noted a recent significant rise in meniscus tear cases. Advances in scientific research and breakthrough discoveries are anticipated to further stimulate market growth by introducing new therapeutic options.

• Several companies, including FUJIFILM Toyama Chemical Co., Ltd., are actively developing drugs in early to mid-phase clinical trials. With the expected approval of these innovative therapies during the forecast period, the overall therapeutic market for meniscus tears is projected to see substantial growth, reflecting a strong compound annual growth rate (CAGR).

Meniscus Tear Epidemiology Segmentation:

• According to Luvsannyam et al. (2022), the incidence of meniscal tears in the US is estimated at 60 per 100,000 people, with a significant rise in related injuries attributed to increased sports participation and advancements in diagnostic technology.

• Masini et al. (2015) reported that, from 2005 to 2012, there were 79 cases of meniscus tears in stable knees among a cohort of 9,086 subjects. Of these, 68 cases (86%) were in males and 11 cases (14%) were in females.

• Leitao et al. (2022) identified several risk factors that elevate the likelihood of meniscal tears. Notably, non-modifiable risk factors include sex, with men experiencing meniscal tears at a rate 2.5 times higher than women.

• Bubnis et al. (2023) found that men over the age of 40 are also at increased risk for meniscal tears.

The Meniscus Tear market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Meniscus Tear

• Gender-specific Prevalence of Meniscus Tear

• Type-specific Prevalence of Meniscus Tear

• Age-specific Prevalence of Meniscus Tear

• Diagnosed Cases of Meniscus Tear

DelveInsight’s comprehensive report provides a thorough exploration of the Meniscus Tear market, covering key Meniscus Tear players, emerging Meniscus Tear therapies, treatment dynamics, and market challenges.

For in-depth insights, access the full report @ Meniscus Tear Market Outlook 2032

Meniscus Tears Emerging Therapy Assessment

The dynamics of the meniscus tear market are expected to evolve significantly in the coming years due to advancements in research and development. The launch of new devices is anticipated throughout the forecast period.

Ceterix Orthopaedics, now acquired by Smith & Nephew, completed the STITCH trial, the first prospective multicenter investigation of suture-based repair for horizontal meniscus tears, a common knee injury. The trial, last updated in December 2020 on clinicaltrials.gov, reported positive results in March 2021. The study involved 23 patients with 2-year follow-up data. Freedom from reoperation was 96.0% at 6 months (26/27), 91.7% at 1 year (23/25), and 82.6% at 2 years (19/23). Significant improvements were observed from baseline at 2 years for IKDC (36.7 to 82.5; P < .001), Knee Injury and Osteoarthritis Outcome Score (52.2 to 89.3; P < .001), Lysholm (50.2 to 87.4; P < .001), and Tegner scores (3.3 to 5.3; P = .007). The minimal clinically important difference was met or exceeded for IKDC and Lysholm scores in 69.2% and 65.4% of patients, respectively. Four patients (6.7%) experienced serious complications, two of which were deemed related to the procedure.

Ortho Regenerative Technologies is developing RESTORE-M, aimed at increasing the number of meniscus repair procedures while reducing meniscectomy procedures. The product, Ortho-M, will be placed into the lesion before it is repaired using the appropriate physical fixation technique. The company plans to complete preclinical studies by 2021 and begin Phase I/II trials.

Request for a sample report @ https://www.delveinsight.com/sample-request/meniscus-tear-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Meniscus Tear Market Growth Anticipated by 2032 | Companies includes Merck, Teva Pharmaceutical, Lipella Pharmaceuticals, Seikagaku Corporation